

Selected recent publications (from a total of 222)

Moshe Oren

1. **Oren, M.** and Levine, A.J. (1983). Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. *Proc. Natl. Acad. Sci. USA.* 80, 56-59.
2. Bienz, B., Zakut-Houri, R., Givol, D. and **Oren, M.** (1984). Analysis of the gene coding for the murine cellular tumor antigen p53. *EMBO J.* 3, 2179-2183.
3. Eliyahu, D., Raz, A., Gruss, P., Givol, D. and **Oren, M.** (1984). Participation of the p53 cellular tumor antigen in transformation of normal embryonic cells. *Nature* 312, 646-649.
4. Zakut-Houri, R., Bienz-Tadmor, B., Givol, D. and **Oren, M.** (1985) Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. *EMBO J.* 4, 1251-1255.
5. Eliyahu, D., Michalovitz, D. and **Oren, M.** (1985) Overproduction of p53 antigen makes established cells highly tumorigenic. *Nature* 316, 158-160.
6. Pinhasi-Kimhi, O., Michalovitz, D., Ben-Zeev, A. and **Oren, M.** (1986) Specific interaction between the p53 cellular tumor antigen and major heat shock proteins. *Nature* 320, 182-185.
7. Eliyahu, D., Michalovitz, M., Eliyahu, S., Pinhasi-Kimhi, O. and **Oren, M.** (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. *Proc. Natl. Acad. Sci. USA* 86, 8763-8767.
8. Michalovitz, D., Halevy, O. and **Oren, M.** (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. *Cell* 62, 671-680.
9. Halevy, O., Michalovitz, D. and **Oren, M.** (1990) Different tumor-derived p53 mutants exhibit distinct biological activities. *Science* 250, 113-116.
10. Ginsberg, D., Michalovitz, D., Ginsberg, D. and **Oren, M.** (1991). Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. *Mol. Cell. Biol.* 11, 582-585.
11. Ginsberg, D., Mechta, F., Yaniv, M., and **Oren, M.** (1991). Wild type p53 can down-modulate the activity of various promoters. *Proc. Natl. Acad. Sci. USA* 88, 9979-9983.
12. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and **Oren, M.** (1991). Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. *Nature* 352, 345-347.
13. Shaulian, E., Zauberman, A., Ginsberg, D., and **Oren, M.** (1992). Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. *Mol. Cell. Biol.* 12, 5581-5592.
14. Barak, Y., Juven, T., Haffner, R. and **Oren, M.** (1993). mdm2 expression is induced by wild type p53 activity. *EMBO J.* 12, 461-468.
15. Zauberman, A., Barak, Y., Ragimov, N., Levy, N., and **Oren, M.** (1993). Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-mdm2 complexes. *EMBO J.* 12, 2799-2808.
16. Juven, T., Barak, Y., Zauberman, A., George, D., and **Oren, M.** (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. *Oncogene* 8, 3411-3416.
17. Gottlieb, E., Haffner, R., von Ruden, T., Wagner, E.F., and **Oren, M.** (1994). Down regulation of wt p53 activity interferes with apoptosis of IL3-dependent hematopoietic cells following IL3 withdrawal. *EMBO J.* 13: 1368-1374.
18. Barak, Y., Gottlieb, E., Juven-Gershon, T., and **Oren, M.** (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with non-identical translation potential. *Genes Dev.* 8, 1739-1749.
19. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K., and **Oren, M.** (1995). Induction of apoptosis in HeLa cells by transactivation-deficient p53. *Genes Dev.* 9, 2170-2183.
20. Haupt, Y., Barak, Y., and **Oren, M.** (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2. *EMBO J.* 15, 1596-1606.
21. Friedlander, P., Haupt, Y., Prives, C., and **Oren, M.** (1996). A mutant p53 that discriminates between p53 responsive genes cannot induce apoptosis. *Mol. Cell. Biol.* 16, 4961-4971.
22. Gottlieb, E., Haffner, R., King, A., Asher, G., Gruss, P., Lonai, P., and **Oren, M.** (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: age and tissue dependent changes in radiation-induced activation during embryogenesis. *EMBO J.* 16, 1381-1390.
23. Haupt, Y., Maya, R., Kazaz, A., and **Oren, M.** (1997). Mdm2 promotes the rapid degradation of p53. *Nature* 387, 296-299.
24. Blandino, G., Levine, A.J., and **Oren, M.** (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. *Oncogene* 18, 477-485.
25. Damalas, A., Ben-Ze'ev, A., Simcha, I., Martinez Leal, J.F., Zhurinsky, J., Geiger, B., and **Oren, M.** (1999). Excess b-catenin promotes accumulation of transcriptionally active p53. *EMBO J.* 18, 3054-3063.
26. Blander, G., Zalle, N., Leal, J.F.M., Lev Bar-Or, R., and **Oren, M.** (2000). The Werner syndrome protein contributes to induction of p53 by DNA damage. *FASEB J.* 14, 2138-2140.

27. Lev Bar-Or, R., Maya, R., Segel, L.A., Alon, R., Levine, A.J., and **Oren, M.** (2000). Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. *Proc. Natl. Acad. Sci. USA* 97, 11250-11255.
28. Maya, R., Balass, M., Kim, S-T., Shkedy, D., Leal, J.F.M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M.B., Katzir, E., and **Oren, M.** (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. *Genes Dev.* 15, 1067-1077
29. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., and **Oren, M.** (2001). Deregulated beta catenin induces p53 through E2F1 and ARF and elicits a p53-dependent senescence-like state. *EMBO J.* 20, 4912-4922.
30. Zalcenstein, A., Stambolsky, P., Muller-Schilling, M., Wallach, D., Goncharov, T.M., Krammer, P.H., and Oren, M. (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. *Oncogene* 22, 5667-5676.
31. Minsky, N., and Oren, M. (2004). The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. *Mol. Cell* 16, 631-639.
32. Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., and **Oren, M.** (2006). Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. *Oncogene* 25, 359-369.
33. Reef, S., Zalckvar, E., Shifman, O., Bialik, S., Sabanay, H., **Oren, M.** and Kimchi, A. (2006). A novel mitochondrial form of p19ARF induces autophagy and Caspase-independent cell death. *Mol. Cell* 22, 463-475.
34. Aylon, Y., Michael, D., Shmueli, A., Yabuta, N., Nojima, H., and **Oren, M.** (2006) The tumor suppressor Lats2 activates p53 in response to mitotic spindle damage and centrosome stress to trigger a G1 tetraploidy checkpoint. *Genes Dev.* 20, 2687-2700.
35. Moskovits, N, Kalinkovich, A., Bar, J., Lapidot, Z. and **Oren, M.** (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. *Cancer Res.* 66, 10671-10676 (priority report).
36. Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M., Levrero, M., Strano, S., Gorgoulis, V.G., Rotter, V., Blandino, G., and **Oren, M.** (2007). Mutant p53 enhances NF-kB activation by tumor necrosis factor alpha in cancer cells. *Cancer Res.* 67, 2396-2401 (priority report).
37. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., and **Oren, M.** (2007). Induction of miR-34a by p53 mediates antiproliferative effects. *Mol. Cell* 26, 731-743.
38. Minsky, N., Shema, E., Field, Y., Schuster, M., Segal, E. and **Oren, M.** (2008). Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. *Nature Cell Biology* 10, 483-488.
39. Shema, E., Tirosh, I., Aylon, Y., Huang, J., Ye, C., Moskovits, N., Raver-Shapira, N., Minsky, N., Pirngruber, J., Tarcic, G., Hublarova, P., Moyal, L., Gana-Weisz, M., Shiloh, Y., Yarden, Y., Johnsen, S.J., Vojtesek, B., Berger, S.L., and **Oren, M.** (2008). The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. *Genes Dev.* 22, 2664-2676.
40. Abe, Y., Oda-Sato, E., Tobiume, K., Kawachi, K., Taya, Y., Okamoto, K., **Oren, M.**, and Tanaka, N. (2008). Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. *Proc. Natl. Acad. Sci. USA* 105, 4838-4843.
41. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, **Oren M**, Strano S, Blandino G, Sacchi A. (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. *Cell Cycle* 7, 1870-1879.
42. Ofir-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M.B. and Oren, M. (2008). Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. *Mol. Cell* 32, 180-189.
43. Brosh, R., Shalgi, R., Liran, A., Landan, G., Korotayev, K., Nguyen, G., Enerly, E., Johnsen, H., Buganim, Y., Solomon, H., Goldstein, I., Madar, S., Goldfinger, Børresen-Dale, A-L, Ginsberg, D., Harris, C.C., Pilpel, Y., Oren, M., and Rotter, V. (2008). p53-repressed miRNAs are involved with E2F in a feed forward loop promoting proliferation. *Mol. Sys. Biol.* 4, 229.
44. Bar J., Feniger-Barish R., Lukashchuk N., Shaham H., Moskovits, N., Goldfinger N., Simansky D., Perlman M., Papa M., Yosepovich A., Rechavi G., Rotter V., and Oren M (2009). Cancer cells suppress p53 in adjacent fibroblasts. *Oncogene* 28, 933-936.
45. Levine, A.J., and Oren, M. (2009). The first 30 years of p53: growing ever more complex. *Nature Rev. Cancer* 9, 749-758.
46. Pirngruber, J., Shchebet, A., Schreiber, L., Shema, E., Minsky, R., Chapman, R.D., Eick, D., Aylon, Y., **Oren, M.**, and Johnsen, S.A. (2009). CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. *EMBO Reports* 10, 894-890.
47. Aylon, Y., Yabuta, N., Besserglick, H., Buganim, Y., Rotter, V., Nojima, H., and **Oren, M.** (2009). Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. *Oncogene* 28, 4469-4479.
48. Oren, M., and Rotter, V. (2009). Mutant p53 gain-of-function in cancer. *Cold Spring Harb. Perspect. Biol* (in press).